| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | SZN-8141 (Fzd4/VEGF) Diabetic Macular Edema (DME), neovascular Age Related Macular Degeneration (wet AMD) | Pre-clinical | — | Subscribe to access the data. | Biologics | Ophthalmologic System | |
IND Submission example | SZN-8141 (Fzd4/VEGF) Diabetic Macular Edema (DME), neovascular Age Related Macular Degeneration (wet AMD) | Pre-clinical | — | Subscribe to access the data. | Biologics | Ophthalmologic System | |
IND Submission example | SZN-8141 (Fzd4/VEGF) Diabetic Macular Edema (DME), neovascular Age Related Macular Degeneration (wet AMD) | Pre-clinical | — | Subscribe to access the data. | Biologics | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Surrozen, Inc.$21.64
+0.07 (+0.32%)
Market Cap
251.25 M
EPS
-29.50
P/E Ratio
-
Value Trade
1.90 M
SEC Financials
Q1 2026Dilution Risk
Revenue
5.00 M
R&D Expenses
9.33 M
Operating CF
-12.49 M
Total Assets
120.71 M
Total Liabilities
398.86 M
Equity
-278.15 M
3.89 %
Week
-5.95 %
1 Month
-29.63 %
3 Month
1.84 %
6 Month
-82.2 %
5 Year
-82.41 %
All Time
Cash Data
Cash Position
106.91 M
Monthly Burn
4.17 M
Runway
22.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
211.71 K
52 Week Range
9.03 - 35
% held by Insiders
49.18 %
% held by Institutions
55.3 %
Enterprise Value
144.34 M
Total Shares
11.61 M
Short %
16.46 %
Float Shares
4.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Surrozen, Inc.
199Total events
0Upcoming
24Tier-1 (high impact)
2019 – 2026Coverage
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SZN-043 | liver cirrhosis | Phase 1a | 2024-06-10 | 40 healthy volunteers; 8 patients with a history of liver cirrhosis; doses ranged from 0.5 mg/kg to 3 mg/kg; mild-to-moderate, transient, and dose-related serum transaminase elevations; increased methacetin clearance; increases in alkaline phosphatase (ALP); increases in the portal hepatic filtration rate (HFR) Read More | Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan Read More | |
SZN-043 | liver cirrhosis | Phase 1a | 2024-06-10 | 40 healthy volunteers; 8 patients with a history of liver cirrhosis; doses ranged from 0.5 mg/kg to 3 mg/kg; mild-to-moderate, transient, and dose-related serum transaminase elevations; increased methacetin clearance; increases in alkaline phosphatase (ALP); increases in the portal hepatic filtration rate (HFR) Read More | Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan Read More | |
SZN-043 | liver cirrhosis | Phase 1a | 2024-06-10 | 40 healthy volunteers; 8 patients with a history of liver cirrhosis; doses ranged from 0.5 mg/kg to 3 mg/kg; mild-to-moderate, transient, and dose-related serum transaminase elevations; increased methacetin clearance; increases in alkaline phosphatase (ALP); increases in the portal hepatic filtration rate (HFR) Read More | Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SRZN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SRZN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SRZN▲ +0.3%today
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Surrozen, Inc. reported its financial results for Q2 2026, highlighting plans for an IND submission for SZN-8141 by Q3 2026 and the initiation of the DUET Phase 1b/2a study in diabetic macular edema by year-end 2026. The company also received a favorable ruling from the U.S. Patent Trial and Appeal Board regarding its patent. Despite an increase in operating expenses, Surrozen's cash position remains strong.
Read more →SRZNSurrozen to Present at Upcoming Healthcare Investor Conference - May 12, 2026
Surrozen, Inc. will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company focuses on developing targeted therapeutics that harness Wnt signaling to treat sight-threatening ophthalmic conditions. Interested parties can access the live audio webcast through Surrozen's website.
Read more →SRZN▼ -9.9%on this news
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
Surrozen, Inc. reported its Q1 2026 financial results, highlighting a cash position of $106.9 million and plans to submit an IND application for SZN-8141 for retinal diseases later this year. Despite a significant net loss of $127.5 million, the company remains focused on advancing its pipeline of ophthalmology therapeutics targeting unmet medical needs. The partnership with Boehringer Ingelheim for SZN-413 further strengthens its development efforts.
Read more →SRZNSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 28, 2026
Surrozen, Inc. announced the grant of a non-statutory stock option for 2,020 shares to a new non-executive employee as part of its 2025 Equity Inducement Plan. This grant, approved by the Board's Compensation Committee, aims to attract talent and is priced at $28.14 per share. The stock option vests over four years, reflecting the company's commitment to its workforce and future growth.
Read more →SRZNSurrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Surrozen, Inc. reported its financial results for Q4 and full year 2025, highlighting significant progress in its ophthalmology pipeline. The company plans to submit an IND application for SZN-8141 in the second half of 2026 and has received a milestone payment from Boehringer Ingelheim for SZN-413. Despite a substantial net loss, Surrozen's cash reserves have increased, indicating a strong financial position for future developments.
Read more →SRZNSurrozen to Present at Upcoming March 2026 Healthcare Investor Conference
Surrozen, Inc. announced its participation in the TD Cowen 46th Annual Healthcare Conference on March 4, 2026. The company will present a fireside chat at 1:10 PM Eastern Time. Surrozen focuses on developing Wnt-based therapeutics for sight-threatening ophthalmic conditions, showcasing its commitment to addressing unmet medical needs.
Read more →SRZNSurrozen to Present at Upcoming Healthcare Investor Conference
Surrozen, Inc. (SRZN), a biotechnology company focused on Wnt-based therapeutics, has announced that its management will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026. The company aims to address significant unmet medical needs in sight-threatening ophthalmic conditions. Interested parties can access a live audio webcast of the event through the Surrozen website. Surrozen's innovative approach combines unique antibody engineering with targeted therapy for ocular diseases.
Read more →SRZNSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 23, 2026
Surrozen, Inc. announced the grant of a non-statutory stock option for 3,070 shares to a new non-executive employee as an inducement for employment. This grant, approved by the Compensation Committee, is part of Surrozen's 2025 Equity Inducement Plan and allows the purchase of shares at $24.53 each. The stock options vest over four years, promoting employee retention.
Read more →SRZN▲ +7.3%on this news
Surrozen to Present at Upcoming February 2026 Healthcare Investor Conference
Surrozen, Inc. announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 12, 2026. The presentation will focus on the company's innovative Wnt-based therapeutics aimed at treating sight-threatening ophthalmic conditions. Interested investors can access the live audio webcast through Surrozen's website.
Read more →SRZNSurrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen, Inc. announced its participation in two upcoming healthcare investor conferences, highlighting its focus on developing targeted therapeutics for severe eye diseases. The presentations will occur at the 37th Annual Piper Sandler Healthcare Conference and the 8th Annual Evercore Healthcare Conference. Interested parties can access the webcasts through Surrozen's investor website.
Read more →SRZN▼ -6.3%on this news
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Surrozen, Inc. announced the grant of stock option awards to its new CFO, Andrew P. Maleki, as part of its 2025 Equity Inducement Plan. The grant covers 50,000 shares at a price of $12.94 each and vests over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting top talent.
Read more →SRZNSurrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
Surrozen, Inc. reported its third quarter 2025 financial results, highlighting a net loss of $71.6 million. The company is focused on advancing its ophthalmology pipeline, particularly with its product candidates SZN-8141, SZN-8143, and SZN-413. Surrozen has strengthened its leadership team and secured a partnership with Boehringer Ingelheim to enhance its development capabilities.
Read more →SRZNSurrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Surrozen, Inc. announced the granting of inducement stock option awards covering 45,710 shares of common stock to four newly hired employees under its 2025 Equity Inducement Plan. These awards, sanctioned by the company's Compensation Committee, are intended to incentivize talent acquisition in line with Nasdaq Listing Rule 5635(c)(4). Each stock option grants access to shares at a set price of $12.32. Surrozen focuses on pioneering tissue-specific therapies for severe eye diseases, enhancing its growth prospects in the biotechnology sector.
Read more →SRZN▲ +5.9%on this news
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of l
Surrozen, Inc. reported strong second quarter 2025 financial results, with a notable net income of $39.7 million, reflecting significant growth compared to the previous year. The company has appointed Dr. Daniel Chao as Vice President of Clinical Development and formed a Clinical Advisory Board to enhance its focus on ophthalmology. Surrozen continues to advance its lead candidates, SZN-8141 and SZN-8143, targeting retinal diseases, and has received a key patent to support its innovative therapeutic approaches. The company remains on track to submit an IND application for SZN-8141 by 2026.
Read more →SRZN▼ -9.7%on this news
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Surrozen, Inc. has announced the issuance of U.S. Patent No. 12,297,278, expanding its intellectual property portfolio related to antibody-based molecules targeting the Wnt pathway. This patent covers novel tetravalent Wnt surrogates that enhance signaling through Frizzled and LRP receptors. The company is also advancing its ophthalmology portfolio with promising candidates SZN-8141 and SZN-8143 for retinal diseases.
Read more →SRZNSurrozen Reports First Quarter 2025 Financial Results and Provides Business Update
Surrozen, Inc. announced its financial results for Q1 2025 and a strategic pivot towards ophthalmology, emphasizing its focus on developing novel treatments for severe eye diseases like AMD and diabetic retinopathy. The company discontinued its SZN-043 candidate due to insufficient clinical benefit, reallocating resources to its lead candidates SZN-8141 and SZN-8143, with an expected IND filing in 2026. Surrozen raised $175 million to support its research initiatives amidst a reported net loss of $27 million for the quarter.
Read more →SRZN▲ +5.9%on this news
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Surrozen, Inc. reported its fourth quarter and full year 2024 financial results, emphasizing strong progress in its ophthalmology pipeline. The company secured $175 million in financing to enhance its development of targeted therapeutics addressing severe eye diseases. Despite an increase in net loss to $63.6 million, Surrozen's cash balance improved, and it announced promising advancements in antibody technologies for its pipeline, particularly in treating retinal conditions. Overall, the company continues to prioritize its research capabilities and collaborations in this field.
Read more →SRZNSurrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases Company prioritizes ophthalmology pipeline programs with pote
Surrozen, Inc. has announced an oversubscribed private placement of $175 million targeted at enhancing its ophthalmology pipeline. The funds will be allocated to advance multiple programs through Phase 1 safety and efficacy studies, primarily focusing on serious eye diseases such as retinopathies. The company will discontinue the development of SZN-043 due to insufficient early clinical benefits. This strategic pivot comes alongside a partnership with Boehringer Ingelheim aimed at further developing SZN-413, which shows potential for treating retinal diseases.
Read more →SRZN▼ -5.1%on this news
Surrozen Provides Third Quarter 2024 Financial Results and Business Update Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected
Surrozen, Inc. reported significant advancements in its Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis, with proof-of-concept data expected in 2025. The company also introduced a portfolio of preclinical ophthalmology candidates and received a $10 million milestone payment from Boehringer Ingelheim related to the development of SZN-413. As of the end of September 2024, Surrozen's cash position was $31 million, with reported collaboration revenue of $10 million, marking a substantial year-over-year increase from the previous quarter. Additionally, the company has entered a strategic collaboration with TCGFB to develop antibody therapeutics targeting TGF-beta.
Read more →SRZN▲ +8.7%on this news
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Surrozen, Inc. has announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration to develop SZN-413, a bi-specific antibody targeting retinal vascular diseases. This payment comes as Boehringer moves to advance SZN-413 towards clinical testing, with the potential to restore retinal function in affected patients. The collaboration emphasizes the importance of Wnt signaling modulation in addressing significant vision loss resulting from retinal diseases. Surrozen's innovative approach aims to meet a critical medical need through targeted therapeutic strategies.
Read more →SRZNSurrozen Provides Second Quarter 2024 Financial Results and Business Update Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a tri
Surrozen, Inc. reported its second quarter 2024 financial results and provided updates on its clinical developments. The company is actively enrolling patients in the SZN-043 Phase 1b trial for severe alcohol-associated hepatitis after successfully completing a Phase 1a trial. The presentation of first-in-human trial data at the European Association for the Study of the Liver (EASL) underscored the potential of Surrozen's proprietary SWEETS technology. Despite progress, the financial results revealed a significant net loss compared to the previous year, emphasizing ongoing challenges ahead.
Read more →SRZNSurrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Surrozen, Inc. has published a study in eLife highlighting the potential of its proprietary SWEETS platform to enhance Wnt signaling through targeted protein degradation technologies. The research focuses on two bispecific antibodies that activate Wnt signaling specifically in liver cells, presenting new treatment approaches for severe liver diseases. Additionally, Surrozen's SZN-043 candidate has shown safety and therapeutic engagement in Phase 1 trials for severe alcohol-associated hepatitis. The company continues to explore the applications of its technology in regenerative medicine.
Read more →SRZNSurrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen presented preliminary results for SZN-043 during the EASL 2024 conference, indicating that the drug was safe and well tolerated in a Phase 1a trial involving healthy volunteers and patients with liver cirrhosis. The study showed evidence of target engagement and pharmacodynamic effects on liver function. Additionally, a Phase 1b study is set to enroll patients with severe alcohol-associated hepatitis, which is anticipated to provide further insights into the drug's efficacy. While results are promising, some subjects experienced mild serum transaminase elevations, indicating the need for continued monitoring.
Read more →SRZNSurrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen has commenced dosing its first patient in a Phase 1b clinical trial for SZN-043, a novel treatment aimed at severe alcohol-associated hepatitis. This open-label trial will enroll around 30 patients, evaluating various efficacy and safety endpoints, with proof-of-concept data anticipated in early 2025. Previous Phase 1a results indicated encouraging safety and early signs of potential clinical benefit, addressing a significant gap in treatment options for this liver condition.
Read more →SRZNSurrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Surrozen, Inc. presented promising preclinical data at the ARVO Annual Meeting, showcasing the potential of its antibody-based Wnt mimetic technology for treating cornea endothelial dystrophies and dry eye disease. The data indicated that the Wnt mimetic could stimulate endothelial cell proliferation, reducing corneal edema and promoting tear production. This has significant implications for patients with few effective treatments available for these severe conditions. The company emphasized its continued evaluation of this innovative approach to eye tissue repair and regeneration.
Read more →SRZNSurrozen Provides First Quarter 2024 Financial Results and Business Update SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical d
Surrozen, Inc. (SRZN) reported its first-quarter financial results for 2024, showcasing progress in its SZN-043 clinical development for severe alcohol-associated hepatitis and other Wnt-modulating therapies. The Phase 1a trial for SZN-043 revealed acceptable safety and tolerability. Additionally, Surrozen's research at ARVO 2024 highlighted its antibody-based Wnt mimetic's promise in treating severe eye diseases. However, the company also reported a net loss of $8.8 million and a decrease in cash reserves compared to the prior quarter.
Read more →SRZN▲ +13.4%on this news
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen, Inc. has published promising findings in 'Respiratory Research' regarding their Wnt mimetic antibody technology, indicating its potential in treating pulmonary fibrosis. In preclinical models, Surrozen's SWAP platform significantly reduced inflammation and fibrosis while enhancing lung function. These results suggest that Wnt mimetic agonists may play a crucial role in tissue repair in severe lung diseases such as idiopathic pulmonary fibrosis. The findings highlight Surrozen's innovative approach to targeting the Wnt pathway for therapeutic advancements.
Read more →SRZN▼ -35.7%on this newsshared move
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Surrozen, Inc. has announced a private placement of securities that could yield up to $192.5 million. This funding is intended to support the expansion of a Phase 1b clinical trial for severe alcohol-associated hepatitis. The private placement will close on or about April 4, 2024, pending customary conditions, and includes participation from both new and existing investors. Proceeds are also planned to extend the company’s cash runway through the first half of 2025.
Read more →SRZN▼ -35.7%on this newsshared move
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 -Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events -Phase 1a data demonstrated target en
Surrozen, Inc. announced positive outcomes from its Phase 1a trial of SZN-043, demonstrating acceptable safety, tolerability, and pharmacodynamic effects related to liver function. The trial involved 48 participants and reported no serious adverse events. Encouraged by these results, Surrozen plans to initiate a Phase 1b proof-of-concept trial targeting severe alcohol-associated hepatitis, with expected data in early 2025. The company is also gearing up to present these findings at a medical meeting in 2024.
Read more →SRZN▼ -5.5%on this news
Surrozen Provides Corporate Update on Clinical Programs
Surrozen, Inc. announced a strategic focus on its clinical programs, particularly the development of SZN-043 for alcohol-associated hepatitis. The company has completed enrollment for the Phase 1a trial and anticipates data to be released in Q1 2024, followed by Phase 1b enrollment in 2024. Additionally, Surrozen will discontinue the development of SZN-1326 for inflammatory bowel disease due to difficulties in dose identification and market concerns. The company's financial status remains strong, with a cash runway extending into 2025.
Read more →SRZNSurrozen Provides Third Quarter 2023 Financial Results Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from
Surrozen, Inc. announced its third quarter 2023 financial results and highlighted significant milestones for its research and development projects. The company expects to reveal data from its SZN-043 and SZN-1326 Phase 1a clinical trials in Q1 2024, with further Phase 1b studies planned for 2024. Surrozen also reinforced its intellectual property through two newly granted patents regarding the WNT pathway, and maintains a cash position sufficient to support its operations into 2025, though it reported a net loss for the quarter.
Read more →SRZN▲ +5.5%on this news· ran to -31% by day 3
Surrozen Provides Second Quarter 2023 Financial Results SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZ
Surrozen has reported its second quarter 2023 financial results, highlighting significant progress in its Phase 1a clinical trials for SZN-043 and SZN-1326. The company is focused on clinical validation of its Wnt pathway modulation technologies and expects safety data from ongoing trials by the end of the year. Financially, Surrozen has extended its cash runway into 2025 through strategic prioritization, despite posting a net loss of $9.4 million for the quarter. The company also anticipates additional clinical trial milestones in 2024.
Read more →SRZNSurrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
Surrozen, Inc. has co-authored a study published in Nature Communications, which highlights the effectiveness of a selective Fzd4 Wnt antibody in a preclinical ischemic stroke model. The findings indicate that systemic administration of this antibody significantly reduced blood-brain barrier leakage and improved neurological outcomes. This research may pave the way for novel therapeutic strategies for central nervous system disorders characterized by abnormal blood-brain barrier function, addressing the urgent need for improved stroke treatments.
Read more →SRZNSurrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety d
Surrozen, Inc. reported its first quarter 2023 financial results along with updates on ongoing clinical trials and corporate restructuring. The company continues to enroll patients in Phase 1a trials for its drug candidates SZN-043 and SZN-1326, expecting safety data to be available by the end of 2023. Despite recent challenges, including a workforce reduction and increased net loss, Surrozen anticipates key milestones ahead, including potential proof-of-concept data for additional indications in 2024. The company is focused on using its proprietary technologies to develop targeted therapeutics aimed at significant medical needs.
Read more →SRZNSurrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
Surrozen, Inc. has announced the appointment of Eric Bjerkholt to its Board of Directors, expanding the board to nine members with diverse experience in biotechnology. Bjerkholt, who is currently CFO of Chinook Therapeutics, brings extensive financial leadership expertise and has previously overseen the acquisition of Aimmune Therapeutics by Nestle Health Science. Surrozen, focused on pioneering targeted therapeutics for tissue repair, aims to leverage Bjerkholt's insights to advance its development of drug candidates targeting the Wnt pathway.
Read more →SRZNSurrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expec
Surrozen, Inc. reported its financial results for Q4 and the full year 2022, detailing advancements in its clinical pipeline. The company enrolled its first patient in the SZN-043 Phase 1a trial for chronic liver disease and expects data by the end of 2023. Additionally, Surrozen plans to initiate a Phase 1b trial for severe alcoholic hepatitis in 2024. Despite a net loss of $36 million for the year, the company maintains a cash position expected to fund its operations into the second half of 2024.
Read more →SRZNSurrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
Surrozen, Inc. plans to report its fourth quarter and full year 2022 financial results alongside a corporate update on March 22, 2023. The company aims to discuss pipeline progress during a live audio webcast scheduled for 4:30 PM Eastern Time. Surrozen specializes in developing drug candidates that modulate the Wnt pathway, focusing on diseases such as inflammatory bowel, severe liver, and eye conditions.
Read more →SRZNSurrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
Surrozen, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023. The company is focused on developing targeted therapeutics that selectively activate the Wnt pathway for tissue regeneration across various disease areas. Surrozen's drug candidates, including SZN-1326, SZN-043, and SZN-413, aim to engage the body's biological repair mechanisms. A live audio webcast of the presentation will be available through its Investor Relations website, with an archived edition following the session.
Read more →SRZNSurrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. ( Surrozen or the Company ) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate
Read more →SRZNSurrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studies SZN-1326 preclinical data shows improved intestinal epithelial healing, restored epithelial barrier, and reduced colitis-associated col
Read more →SRZNSurrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
The collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds in development Surrozen's novel antibody-based approach targets Fzd4 biology, which has been shown to play a fundamental role in retinal vascular integrity and function
Read more →SRZN▼ -8.4%on this news
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
Results highlight a potential novel treatment for diabetic and other retinopathies Unique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth into physiological regrowth of retinal blood vessels SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GL
Read more →SRZNSurrozen Reports Second Quarter 2022 Financial Results • Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing • Preclinical proof-of-concept data for multiple programs presented and publish
Surrozen Reports Second Quarter 2022 Financial Results -Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing -Preclinical proof-of-concept data for multiple programs presented and published in Q2 continue to validate Wnt modulation for tissue repair SOUTH SAN
Read more →SRZNSurrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1 First part of two-part Phase 1 trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasd
Read more →SRZN▼ -5.8%on this news
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the presentation of data supporting the continued
Read more →SRZN▲ +7.3%on this news
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP) bi-specific antibody First part of three-part Phase 1/1b trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage
Read more →SRZNSurrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today the publication of an article by Surrozen scientis
Read more →SRZN▼ -8.7%on this newsshared move
Surrozen Reports First Quarter 2022 Financial Results On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022
Surrozen Reports First Quarter 2022 Financial Results On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. ( Surrozen or the Company
Read more →SRZN▼ -12.9%on this news
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, P
Read more →SRZNSurrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that a poster supporting the potential of SZN-413
Read more →SRZN▼ -6%on this news
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 SOUTH SAN FRANCISCO, Calif., March 24, 2022 Surrozen, Inc. ( Surrozen or the Company )
Read more →SRZNSurrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and compelling preclinical data highlighting the potential for lacrimal gland and
Read more →SRZNSurrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 1
Read more →SRZNSurrozen Reports Third Quarter 2021 Financial Results Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Set
Surrozen Reports Third Quarter 2021 Financial Results Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO, Calif., November 15, 2021 Surr
Read more →SRZNSurrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, includi
Read more →SRZNSurrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate
Read more →SRZNSurrozen to Present at The Stifel 2021 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will present at t
Read more →SRZN▼ -5.7%on this news
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its inflammatory bowel disease (IB
Read more →SRZN▼ -9.1%on this news· ran to -25% by day 3
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth “Liz” Nguyen has been appointed as Vice Preside
Read more →SRZNSURROZEN OPERATING, INC. INDEX TO UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Interim Financial Statements for the Three and Six Months Ended
SURROZEN OPERATING, INC. INDEX TO UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Interim Financial Statements for the Three and Six Months Ended June 30, 2021 and 2020 Condensed Balance Sheets 1 Condensed Statements of Operations and Compre
Read more →SRZNSurrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration Common stock and warrants to commence trading on Nasdaq on August 12, 2021 under the ticker symbols SRZN and SRZNW SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) Surrozen, Inc. ( Sur
Read more →SRZNSurrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, chief executive officer, will provide a comp
Read more →SRZNNew Surrozen to Trade on Nasdaq as
New Surrozen to Trade on Nasdaq as SRZN PRINCETON, N.J. July 30, 2021 Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW) ( CHFW ) today announced that, upon the Domestication and the consummation of its pending business combination (the Business Combination ) with Surro
Read more →SRZNSurrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that new data from its inflammatory bowel disease (IBD) program, including pre
Read more →SRZNSurrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that data from preclinical studies of SZN-043 were presented during The Digita
Read more →SRZNSurrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications
SOUTH SAN FRANCISCO, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that data from preclinical studies were presented in four oral Abstract Flash
Read more →SRZNSurrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture
Results Demonstrate Rapid and Robust Bone-building Effects from Selective Wnt Agonists in Proof of Concept, Preclinical Studies of Wnt Mimetics for the Treatment of Diseases of Low Bone Mineral Density Studies Validate Potential of Surrozen’s Wnt Antibody Platform SOUTH SAN FRA
Read more →SRZNSurrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that data from preclinical studies of its two lead Wnt-modulating antibody prog
Read more →SRZNSurrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Mace Rothenberg, M.D., and Christopher Chai to its Board of Dir
Read more →SRZNSurrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration Surrozen expects to receive approximately $212 million in gross proceeds
Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration Surrozen expects to receive approximately $212 million in gross proceeds from the business combination, including $120 million fro
Read more →SRZNSurrozen Expands Board of Directors with Appointment of Mary Haak-Frendscho, Ph.D.
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Mary Haak-Frendscho, Ph.D., to the Board of Directors. Dr. Ha
Read more →SRZNSurrozen Expands Board of Directors with Appointment of Shao-Lee Lin, M.D., Ph.D.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Shao-Lee Lin, M.D., Ph.D. to the Board of Directors. Dr. Lin i
Read more →SRZN: CONSONANCE-HFW ACQUISITION CORP. SECURITIES TO COMMENCE SEPARATE TRADING Princeton, NJ (
FOR IMMEDIATE RELEASE: CONSONANCE-HFW ACQUISITION CORP. SECURITIES TO COMMENCE SEPARATE TRADING Princeton, NJ (January 7, 2021) - Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW.U) ("Consonance-HFW") announced today that separate trading of its common stock and war
Read more →SRZNINDEX TO FINANCIAL STATEMENT Audited Financial Statement for Consonance-HFW Acquisition Corp.: Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F- 1 REPO
INDEX TO FINANCIAL STATEMENT Audited Financial Statement for Consonance-HFW Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders an
Read more →SRZNConsonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering
Acquisition Corp. Announces Pricing of Its Initial Public Offering 18, 2020 - Consonance-HFW Acquisition Corp. ("Consonance-HFW") announced today the pricing of its initial public offering of 8,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proc
Read more →SRZNSurrozen to Present at the Stifel 2020 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel
Read more →SRZNSurrozen Appoints Charles Williams as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the appointment of Charles Williams as chief financial officer. An experienced biopharmaceutical execu
Read more →SRZNSurrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to support development of SZN-043, a novel liver-targeted regenerative antibody. The NIH
Read more →SRZNSurrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the addition of David J. Woodhouse, Ph.D., to the Board of Directors. Dr. Woodhouse currently serves
Read more →SRZNSurrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference
-- Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine -- SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced tha
Read more →SRZNSurrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports
-- Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies,
Read more →SRZNSurrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful completion of a $50 million Series C financing. Investors from the Series B financing p
Read more →SRZNSurrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration
-- Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online -- SOUTH SAN FRANCISCO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced tod
Read more →SRZNSurrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research
SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that one of its scientific founders, Dr. Roel Nusse, received the 2020 Canada Gairdner International
Read more →SRZNSurrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology
-- Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, toda
Read more →SRZNSurrozen to Present at Cowen and Company 40th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Surrozen, Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues, today announced that President & Chief Executive Officer, Craig Parker, will pres
Read more →SRZNSurrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the appointment of Trudy Vanhove, MD, PhD,
Read more →SRZNSurrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates
-- Anna Berkenblit, MD, appointed to Surrozen Board of Directors -- SAN FRANCISCO, March 14, 2019 (GLOBE NEWSWIRE) -- Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, tod
Read more →Competitive Position
How SRZN ranks across every disease it competes inCompetitive Position is a premium feature
See how SRZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial